Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

LNP Strategy

Building Better RNA Medicines Through Smarter LNP Formulation Strategy

Aula Al Muslim, Ph.D.

Recipharm Advanced Bio

U.S. CDMO Capacity

More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Pharma's Almanac

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?

Pharma's Almanac

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac

ADCs

Re-Engineering ADCs for Autoimmune and Inflammatory Disease

David Alvaro, Ph.D.

Pharma's Almanac

Conjugation

Why ADC Conjugation Strategy Is Now a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

ADC Platform

From mAbs to ADCs: Rethinking the Platform Manufacturing Model

David Alvaro, Ph.D.

Pharma's Almanac

HACs

Synthetic Chromosome Therapeutics: Expanding Genomic Medicine Beyond the Limits of Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

ADC Linkers

Linker Chemistry as the Hidden Determinant of ADC Success

David Alvaro, Ph.D.

Pharma's Almanac

Oligo Delivery

Expanding the Reach of Oligonucleotide Drugs Through Delivery Innovation

David Alvaro, Ph.D.

Pharma's Almanac

ADC Engineering

Engineering Antibodies for Precision Payload Delivery

David Alvaro, Ph.D.

Pharma's Almanac

Conjugate Payloads

Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

CRISPR vs. Base Editing vs. Prime Editing: Which Genome Editing Technology Is Best?

Pharma's Almanac